Isomorphic Labs, the Alphabet spinoff, released IsoDDE on February 10, a unified drug design engine that achieves a 50% success rate on the hardest molecular prediction tasks, outperforming AlphaFold …
Apple Inc. has sent document retention letters to dozens of OpenAI employees as part of a widening trade secrets lawsuit that claims over 400 former Apple employees now work at OpenAI, threatening the…
Isomorphic Labs unveiled the Isomorphic Labs Drug Design Engine (IsoDDE), a unified computational drug-design system that more than doubles the accuracy of AlphaFold 3 on a challenging protein-ligand …
Google DeepMind philosopher Iason Gabriel works to anticipate the ethical fallout of AI, bridging the gap between AI safety and AI ethics. His 2020 paper on values and alignment argues that choosing w…
Google DeepMind has launched a bioresilience programme to use AI to prevent, detect and respond to biological threats, the London lab and its sister company Isomorphic Labs announced in a joint blog p…
Google DeepMind and Isomorphic Labs have announced a joint initiative on bioresilience, using AI to predict and defend against biological threats, building on AlphaFold technology. Isomorphic Labs, fo…
Google DeepMind and Isomorphic Labs released a joint approach to bioresilience, outlining how AI can prevent misuse of models, detect outbreaks, and accelerate response. The companies have advanced mo…
OpenAI researcher Miles Wang is leaving to launch an AI drug discovery startup in talks to raise about $200 million at a $2 billion valuation, with Lightspeed in discussions to lead the round, though …
OpenAI researcher Miles Wang is in talks to launch an AI drug discovery startup at a $2 billion pre-money valuation, with Lightspeed Venture Partners in discussions to lead a ~$200 million round. The …
OpenAI researcher Miles Wang is leaving the ChatGPT maker to launch an AI drug discovery startup valued at $2 billion, with plans to raise about $200 million from Lightspeed, according to sources. The…
Temasek Holdings plans to triple its AI investments from $25 billion to $75 billion by 2030, joining funding rounds for Anthropic, Waymo, and Isomorphic Labs as part of a broader restructuring to inte…
Google DeepMind's AlphaFold 3 predicts interactions among proteins, DNA, RNA, ligands, and other biomolecules, while Isomorphic Labs introduced the Isomorphic Drug Design Engine (IsoDDE) for drug disc…
Anthropic announced Claude Science, an AI workbench for scientists, and revealed plans to develop its own drugs targeting neglected diseases, marking one of the most direct attempts by a major AI comp…
Eli Lilly invested $40 million in Absci, a generative AI drug company, to develop ABS-201, an injectable antibody for baldness and endometriosis. The deal, part of a $100 million stock offering, aims …
Google Cloud will offer specialist AI models from SandboxAQ, called large quantitative models, through its marketplace, pairing them with Gemini to serve scientific fields like drug discovery and mate…
Isomorphic Labs, a Google DeepMind spinoff, has developed a new AI system called the Isomorphic Drug Design Engine (IsoDDE) to identify hidden binding sites on proteins that standard models like Alpha…
Isomorphic Labs, the AI drug discovery startup spun out of Google DeepMind in 2021, raised a new $2.1 billion Series B led by Thrive Capital to scale its computing power and drug development programs.…
SandboxAQ has partnered with Anthropic to integrate its physics-based AI models, known as Large Quantitative Models (LQMs), into Claude, allowing researchers to perform complex drug discovery and mate…